Research Topics
| D ReySummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virusD Rey
CISIH, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
J Med Virol 57:75-9. 1999....
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patientsD Rey
COREVIH, Hopitaux Universitaires, Strasbourg, France
J Antimicrob Chemother 63:380-8. 2009..The once-daily combination of lamivudine, tenofovirDF and nevirapine has not been evaluated in a clinical trial...- Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patientsDavid Rey
Centre d information et de soins de l immunodeficience humaine, Clinique Medicale A, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg, France
J Acquir Immune Defic Syndr 43:530-4. 2006..A regimen of once-daily zidovudine (ZDV), 3TC, ABC, and TDF showed an acceptable virologic success rate, however... - [Hepatitis A seroprevalence in HIV-infected patients]D Rey
Centre d information et de soins de l immunodeficience humaine, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg Cedex, France
Med Mal Infect 35:402-6. 2005..The authors had for aim to prospectively study the hepatitis A seroprevalence of an HIV-infected population, followed-up in an outpatient clinic (CISIH Strasbourg)... - Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIVDavid Rey
Hopitaux Universitaires Strasbourg, Strasbourg, France
J Acquir Immune Defic Syndr 37:1454-6. 2004..We believe that such a short course (4 days) of 200-mg NVP treatment once a day in combination with 2 nucleoside analogues for 1 month is clinically and biologically safe... - [Osteopathies that weaken HIV-infected patients]David Rey
CISIH, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg
Presse Med 32:1857-63. 2003..However, it is probable that the classical risk factors for osteoporosis are often implied... - Prevalence and persistence of TT virus DNA in HIV1-infected individualsD Rey
Center for Human Immunodeficiency Disease, Medical Clinic, University Hospital, Place de l Hôpital 1, F 67091 Strasbourg, France
Infection 31:226-31. 2003..TT virus (TTV) is a recently discovered virus with a high DNA prevalence in different populations. Its role in pathogenesis is uncertain, particularly in immunocompromised patients... - [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results]D Rey
CISIH, Clinique Medicale A, Hopitaux Universitaires, 1, Place de l Hopital, 67091 Strasbourg, France
Pathol Biol (Paris) 49:559-66. 2001..Treatment re-initiation induces a good response, but virologically transient in most cases. Patients with a shift to wild-type virus seem to have a better response... - Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapyD Rey
Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
Eur J Clin Microbiol Infect Dis 18:137-41. 1999..In cases of Aspergillus renal abscess in HIV-infected patients, surgery is the treatment of choice, especially in the current era of highly active antiretroviral therapy... - Post-exposure prophylaxis for HIV infectionDavid Rey
Le Trait d Union, Centre de Soins de l Infection par le VIH, NHC, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg, France
Expert Rev Anti Infect Ther 9:431-42. 2011..The initial evaluation of an exposed individual is presented, as well as the follow-up during and after treatment... - Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral loadD Rey
CISIH, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
Vaccine 18:1161-5. 2000..The effects on HIV-1 viral load are limited... - High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1D Rey
CISIH, Clinique Médicale A Hôpitaux Universitaires, Strasbourg, France
Eur J Clin Microbiol Infect Dis 19:721-4. 2000..GBV-C/HGV infection was frequent in this group of HIV-infected patients and was associated with older age, lower CD4 + cell counts, and the presence of hepatitis B surface antigen... - Quantitation of hepatitis C virus RNA in saliva and serum of patients coinfected with HCV and human immunodeficiency virusD Rey
Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
J Med Virol 63:117-9. 2001..003), but not between quantifications (P = 0.57). This first study reporting significant amounts of HCV RNA in saliva could have important implications for HCV epidemiology... - Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeksD Rey
Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, 1 Place de l Hopital, 67091 Strasbourg Cedex, France
J Acquir Immune Defic Syndr 27:459-62. 2001..One AIDS patient experienced a single cutaneous recurrence of Kaposi's sarcoma after 40 weeks on EFV. Replacing PI with EFV in patients with optimal pVL suppression appears to be safe both virologically and immunologically... - Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG studyLionel Piroth
Infectious Diseases Department, University Hospital, and University of Burgungy, Dijon, France
Hepatology 52:1915-21. 2010..The duration of treatment should be modulated according to RVR, with a 24-week course for patients presenting RVR and a 48-week course for those who do not, irrespectively of HCV genotype... - Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled studyJean Jacques Parienti
Epidemiologie, Systemes d Informations, Modelisation, Institut National de la Sante et de la Recherche Medicale U707, Paris, France
Clin Infect Dis 45:263-6. 2007..04). A switch to nevirapine was associated with no severe adverse events... - First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomesValerie Potard
INSERM, UMR S 720, Paris, France
Antivir Ther 12:317-24. 2007.... - Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)Lionel Piroth
Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
AIDS 21:1323-31. 2007..To describe the characteristics of hepatitis B (HBV) infection in HIV-infected patients and the impact of anti-HBV treatments...